Clinical Trial Update: EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects [NA]

View source ↗

Summary

The clinical trial update indicates that the EndoBarrier SANS study in overweight or obese individuals with type 2 diabetes has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• EndoBarrier SANS

Snippet

Sponsor: Morphic Medical Inc. | Conditions: Obesity, Type 2 Diabetes | NA | Status: TERMINATED